Summary
This 8-K filing from Edwards Lifesciences Corporation (EW), dated July 24, 2006, announces the company's financial results for the second quarter of 2006. The primary purpose of this report is to disclose the company's performance and financial condition as of and for the period ended on that date. Investors should pay close attention to the press release (Exhibit 99.1) attached to this filing, as it contains the detailed financial figures and operational highlights for the quarter. The information presented in this 8-K, particularly within the press release, is crucial for understanding Edwards Lifesciences' recent operational success and its financial standing. While the 8-K itself is a brief regulatory document, the incorporated press release will offer insights into key metrics such as revenue, profitability, and potentially any significant business developments or outlook that would influence investment decisions.
Key Highlights
- 1Edwards Lifesciences Corporation filed a Form 8-K on July 24, 2006.
- 2The filing primarily reports on the company's financial results for the second quarter of 2006.
- 3Exhibit 99.1, a press release dated July 24, 2006, contains the detailed financial results for Q2 2006.
- 4This press release is furnished under Item 2.02 (Results of Operations and Financial Condition).
- 5Certain information within Exhibit 99.1 (first two paragraphs and pages 6-10) is deemed filed under the Exchange Act.
- 6The Chief Financial Officer, Thomas M. Abate, signed the report, indicating official company confirmation of the disclosed information.
- 7The filing does not contain any new material agreements, amendments, or other significant corporate events beyond the quarterly financial results announcement.